MedTrace Logo

Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine

NCT04691908 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2023-12-13

No results posted yet for this study

Summary

Multicenter, randomized, blind, placebo-controlled clinical study of III phases on the assessment of preventive efficiency, safety and immunogenicity QazCovid-in®-vaccine against COVID-19 in healthy adult volunteers

Conditions

  • Covid19
  • SARS-CoV Infection
  • Vaccine Adverse Reaction

Interventions

BIOLOGICAL

QazCovid-in®-vaccine against COVID-19

QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan

OTHER

Placebo

Placebo (sodium chloride buffs, solvent for the preparation of dosage forms for injection 0.9%)

Sponsors & Collaborators

  • City polyclinic No. 4 of the of Almaty Ministry of Healthcare of the Republic of Kazakhstan

    collaborator UNKNOWN

  • Clinic of the International Institute of Postgraduate Education Ministry of Healthcare of the Republic of Kazakhstan

    collaborator UNKNOWN

  • City Multidisciplinary Hospital of Zhambyl Region Ministry of Healthcare of the Republic of Kazakhstan

    collaborator UNKNOWN

  • Research Institute for Biological Safety Problems

    lead OTHER_GOV

Principal Investigators

  • Berik Khairullin, PhD · Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan

  • Kunsulu Zakarya, PhD · Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan

  • IIlyas Kulmagambetov, PhD · Centre for Clinical Medicine and Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-25
Primary Completion
2021-04-26
Completion
2021-07-11

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04691908 on ClinicalTrials.gov